// App-Quantinova.ai

193 : Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.

Researchers

Presenter

  • Eric Van Cutsem

Principal Investigators

  • Junji Furuse

  • Josep Tabernero

  • Volker Heinemann

  • Tatsuya Ioka

  • Igor Bazin

  • Makoto Ueno

  • Tibor Csszi

  • Harpreet Wasan

  • Bohuslav Melichar

  • Petr Karasek

  • Teresa Macarulla

  • Carmen Guilln Ponce

  • Ewa Kalinka-Warzocha

  • Zsolt Horvath

  • Hans Prenen

  • Michael Schlichting

  • Fazal Mehdi

  • Johanna C. Bendell

Medical Centers

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Tokyo University Hospital, Tokyo, Japan

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • University of Munich, Munich, Germany

  • Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan

  • N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

  • Kanagawa Cancer Center, Yokohama, Japan

  • Jasz-Nagykun Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic

  • Masaryk Memorial Cancer Institute, Brno, Czech Republic

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Hospital Ramon y Cajal, Madrid, Spain

  • Wojewodzki Szpital Specjalistyczny im Kopernika, Lodz, Poland

  • Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen, Hungary

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono, Inc, Billerica, MA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • Belgium

  • United States

  • Japan

  • Spain

  • Germany

  • Russia

  • Hungary

  • United Kingdom

  • Czech Republic

  • Poland

Companies

  • EMD Serono Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • Evofosfamide

  • Gemcitabine

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01144455

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved